Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Anticoagulant Fraction from the Leaves of Diospyros Kaki L. Has an Antithrombotic Activity

  • Sa You Seon (Department of Biological Sciences, University of Ulsan) ;
  • Kim Soo-Jin (Department of Biological Sciences, University of Ulsan) ;
  • Choi Hye-Seon (Department of Biological Sciences, University of Ulsan)
  • Published : 2005.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

The leaves of Persimmon (Diospyros kaki L.) has long been used for tea in Korea since it was thought to be effective against hypertension. An anticoagulant fraction was purified through gel filtration G-100, hydrophobic, gel filtration G-150, and FPLC, Phenyl superpose column chromatographies. The purified fraction was homogenous and its Mr was estimated 10,000 Da by gel filtration and SDS-PAGE. The purified fraction was sensitive to treatment of subtilisin B, but not to heat and its activity was not changed after periodate oxidation, indicating that the activity was not due to carbohydrates. It delayed thrombin time (TT), activated partial thromboplastin time (APTT), and prothrombin time (PT) using human plasma. TT was more sensitive than APTT and PT, suggesting that the anticoagulant activity may be caused by a degradation or a defect of fibrin or thrombin. It did not cause the hydrolysis of fibrin after incubation. However, it inhibited thrombin-catalyzed fibrin formation with a competitive inhibition pattern. These results indicate that it may be an antithrombotic agent and that it is bound to fibrinogen binding sites of thrombin.

Keywords

References

  1. Carter, W. J., Myles, T., Gibbs, C. S., Leung, L. L., and Huntington, J. A., Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. J. Biol. Chem., 279, 26387-26394 (2004) https://doi.org/10.1074/jbc.M402364200
  2. Cho, J., Seo, H., Yun, C., Koo, B., Yoshida, S., Koga, T., Dan, T., and Kim, H., In vitro and in vivo stuies of AT-1362, a newly synthesized and orally active inhibitor of thrombin. Thromb. Res., 100, 97-107 (2000) https://doi.org/10.1016/S0049-3848(00)00298-X
  3. Cho, H. R. and Choi, H. S. Effects of anticoagulant from Spirodela polyrhiza in rats. Biosci. Biotechnol. Biochem., 67, 881-883 (2003) https://doi.org/10.1271/bbb.67.881
  4. Choi, H. S. and Sa, Y. S., Fibrinolytic and antithrombotic protease from Spirodela polyrhiza. Biosci. Biotechnol. Biochem., 65, 781-786 (2001) https://doi.org/10.1271/bbb.65.781
  5. Friedrich, T., Kroger, B., Bialojan, S., Lemaire, H. G., Hoffken, H. W., Reuschenbach, P., Otte, M., and Dodt, J., A kazal-type inhibitor with thrombin specificity from Rhodnius prolixus. J. Biol. Chem., 268, 16216-16222 (1993)
  6. Herbert, J. M., Herault, J. P., Bernat, A., van Amsterdam, R. G. M., lormeau, J. C., Petitou, M., van Boeckel, C., Hoffmann, P., and Meuleman, D. G., Biochemical and pharmacological properties of Sanorg 34006, a potent and long-acting synthetic pentasaccharide. Blood, 91, 4197-4205 (1998)
  7. Hofmann, W. and Bon, C., blood coagulation induced by the venom of Bothrops atrox. 1. Identification, purification, and properties of a prothrombin activator. Biochemistry, 26, 772-776 (1987) https://doi.org/10.1021/bi00377a018
  8. Holsat, J., Lindblad, B., and Bergqvist, D., Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis-a comparison with low molecular weight heparin. Thromb. Haemost., 71, 214-219 (1994)
  9. Jakubowski, J. A. and Maraganore, J. M., Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood, 75, 399-406 (1990)
  10. Kang, K. T., Jung, B. I., Bae, O. N., Lee, M. Y., Chung, S. M., Lee, J. Y., Lee, S. K., Kim, I. C., and Chung, J. H., Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. Thromb. Haemost., 89,104-111 (2003)
  11. Lettino, M. and Toschi, V., Direct antithrombins: new perspectives in cardiovascular medicine. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 2, 267-275 (2004) https://doi.org/10.2174/1568016043356291
  12. Liu, F., Craft, R. M., Morris, S. A., and Carroll, R. C., Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert. Opin. Investig. Drugs, 9, 2673-2687 (2000) https://doi.org/10.1517/13543784.9.11.2673
  13. Markwardt, F., Hirudin as alternative anticoagulant-a historical review. Semin. Thromb. Hemost., 28, 405-414 (2002) https://doi.org/10.1055/s-2002-35292
  14. McClanahan, T. B., Hicks, G. W., Morrison, A. L., Peng, Y. W., Janiczek-Dolphin, N., Mertz, T. E., Sullivan, M. E., Morser, J., Juneau, P. L., and Leadley, R., The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur. J. Pharmacol., 432,187-194 (2001) https://doi.org/10.1016/S0014-2999(01)01090-1
  15. McGowan, E. B. and Detwiler, T. C., Modified platelet responses to thrombin. Evidence for two types of receptors or coupling mechanisms. J. Biol. Chem., 261, 739-746 (1986)
  16. Moon, K. S., In Usage of Herbal Medicine (ed. Choi, O. J.), pp 466-468, Ilwolseogak (1991)
  17. Muramatsu, R., Sasaki, M., Watanabe, N., Goto, Y., Okayama, T., Nukui, E., Morikawa, T., and Hayashi, H., Antithrombotic effects of NE-6505, a novel anion-binding exosite inhibitor. Thromb. Res., 86, 453-460 (1997) https://doi.org/10.1016/S0049-3848(97)00094-7
  18. Naski, M. C., Fenton II, J. W., Maraganore, J. M., Olson, S. T., and Shafer, J. A., The COOH-terminal domain of hirudin. J. Biol. Chem., 265, 13484-13489 (1990)
  19. Noeske-Jungblut, C., Haendler, B., Donner, P., Alagon, A., Possani, L., and Schleu ning, W-D., Triabin, a highly potent exosite inhibitor of thrombin. J. Biol. Chem., 270, 28629-28634 (1995) https://doi.org/10.1074/jbc.270.48.28629
  20. Okonogi, T., Hattori, Z., Ogiso, A., and Mitsui, S., Detoxification by persimmon tannin of snake venoms and bacterial toxins. Toxicon, 17, 524-527 (1979) https://doi.org/10.1016/0041-0101(79)90287-3
  21. Olson, S. T., Bjo, I., Sheffer, R., Craig, P. A., Shore, J. D., and Choay, J., Role of the antithrombin-binding pentasaccharides in heparin acceleration of antithrombin-proteinase reactions. J. Biol. Chem., 267, 12528-12538 (1992)
  22. Rezaie, A. R., Cooper, S. T., Church, F. C., and Esmon, C. T., Protein C inhibitor is a potent inhibitor of the thrombinthrombomodulin complex. J. Biol. Chem., 270, 25336-25339 (1995) https://doi.org/10.1074/jbc.270.43.25336
  23. Renda, G., Rocca, B., Crocchiolo, R., Cristofaro, R.D., and Landolfi, R., Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thromb. Haemost., 89, 348-354 (2003)
  24. Richardson, J. L., Kroger, B., Hoeffken, W., Sadler, J. E., Pereira, P., Huber, R., Bode, W., and Fuentes-Prior, P., Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. EMBO J., 19, 5650-5660 (2000) https://doi.org/10.1093/emboj/19.21.5650
  25. Sa, Y. S., Kim, K. A., and Choi, H. S., Purification and characterization of anti-coagulant activity from persimmon stem. J. Kor. Soc. Food Sci. Nutr., 32, 1323-1327 (2003) https://doi.org/10.3746/jkfn.2003.32.8.1323
  26. Strube, K.-H., Kroger, B., Bialojan, S., Otte, M., and Dodt, J., Isolation, sequence analysis, and cloning of haemadin. J. Biol. Chem., 268, 8590-8595 (1993)
  27. Stubbs, M. T., Oschkinat, H., Mayr, I., Huber, R., Angliker, H., Stone, S. R., and Bode, W., The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur. J. Biochem., 206, 187-195 (1992) https://doi.org/10.1111/j.1432-1033.1992.tb16916.x
  28. Tsiang, M., Lentz, S. R., Dittman, W. A., Wen, D., Scarpati, E. M., and Sadler, J. E., Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. Biochemistry, 29, 10602-10612 (1990) https://doi.org/10.1021/bi00499a005
  29. Wall, D., Douglas, S., Ferro, V., Cowden, W., and Parish, C., Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb. Res., 103, 325-335 (2001) https://doi.org/10.1016/S0049-3848(01)00314-0
  30. Wong, P. C., Crain, E. J., Watson, C. A., Zaspel, A. M., Wright, M. R., Lam, P. Y., Pinto, D. J., Wexler, R. R., and Knabb, R. M., Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J. Pharmacol. Exp. Ther., 303, 993-1000 (2002) https://doi.org/10.1124/jpet.102.040089
  31. Yuk, D. Y., Ryu, C. K., Hong, J. T., Chung, K. H., Kang, W. S., Kim, Y., Yoo, H. S., Lee, M. K., Lee, C. K., and Yun, Y. P., Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative. Biochem. Pharmacol., 60, 1001-1008 (2000) https://doi.org/10.1016/S0006-2952(00)00411-1